Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; 3 of the 64 sources its claims cite were checked for support.
Abstract
Purpose/Background: A recent years' increase in both prescribing and availability of second-generation antipsychotics (SGAs) has been observed. According to the literature, typically made up by case studies/series, quetiapine seems to be the most commonly misused SGA, with both intranasal and intravenous intake modalities having been described. Another SGA that has been anecdotally reported to be misused is olanzapine. For these molecules, both a previous history of drug misuse and being an inmate have been described as factors associated with misuse. Hence, while providing here an updated literature review of the topic, we aimed at assessing all cases of quetiapine misuse/abuse/dependence/withdrawal as reported to the European Medicines Agency's EudraVigilance (EV) database; this was carried out in comparison with the reference drug olanzapine. Methods: All spontaneous, European Medicines Agency database reports relating to both quetiapine (2005–2016) and olanzapine (2004–2016) misuse/abuse/dependence/withdrawal issues were retrieved, and a descriptive analysis was performed. Results: From the EV database, 18,112 (8.64% of 209,571) and 4178 (7.58% of 55,100) adverse drug reaction reports of misuse/abuse/dependence/withdrawal were associated with quetiapine and olanzapine, respectively. The resulting proportional reporting ratio values suggested that the misuse/abuse–, dependence-, and withdrawal-related adverse drug reactions were more frequently reported for quetiapine (1.07, 1.01, and 5.25, respectively) in comparison with olanzapine. Conclusions: Despite data collection limitations, present EV data may suggest that, at least in comparison with olanzapine, quetiapine misuse may be a cause for concern.
Overview
CoChat Summary
TL;DR
In an EMA EudraVigilance analysis and literature review, quetiapine was associated with more misuse/abuse/dependence/withdrawal ADR reports than olanzapine, with a particularly high withdrawal PRR. The authors conclude quetiapine misuse may be a cause for concern relative to olanzapine, despite spontaneous-report limitations.
Key findings
- From the EV database, quetiapine had 18,112 misuse/abuse/dependence/withdrawal ADRs (8.64% of 209,571 total ADRs; 884 patients) versus olanzapine with 4,178 (7.58% of 55,100; 237 patients).
- PRR values for quetiapine versus olanzapine were 1.07 for misuse/abuse, 1.01 for dependence, and 5.25 for withdrawal.
- Fatalities were identified in 368 quetiapine cases (45.2%; 2,979 ADRs) and 79 olanzapine cases (34.6%; 687 ADRs); the drug was reported on its own in only 5 quetiapine and 1 olanzapine case.
- Most quetiapine ADRs were drug abuse (52.21%), drug dependence (26.43%), and substance abuse (7.6%); olanzapine ADRs were drug abuse (55.43%) and drug dependence (29.94%). Quetiapine IR formulations were involved in 2,122/2,265 (93.7%) cases where formulation was known; there were 22 quetiapine nasal insufflation and 18 parenteral/intravenous cases versus 1 and 7 for olanzapine.
Methods
- Design: updated literature review plus descriptive analysis of spontaneous ADR reports in the EMA EudraVigilance database, comparing quetiapine with olanzapine.
- Data: quetiapine reports from 07/2005–07/2016 and olanzapine reports from 09/2004–07/2016; SMQ “drug abuse, dependence and withdrawal” terms included dependence, drug abuse, drug dependence, drug withdrawal syndrome, intentional product misuse, substance abuse, substance dependence, and withdrawal syndrome.
- Analysis: descriptive counts and proportional reporting ratio (PRR), where PRR >1 suggests the adverse event is more commonly reported for the drug of interest relative to the comparator.
Limitations
- The paper states: spontaneous case reports rarely confirm causality; reporting depends on market availability/use, reaction nature, and awareness, so comparing report counts may mislead; reports likely reflect prescribed drugs only, not rogue websites or OTC availability; comparison assumes similar non-misuse AE profiles though profiles differ; global prescribing figures are unavailable; misuse/abuse/dependence/withdrawal are not the same issues and withdrawal alone does not indicate misuse/recreational value; duplicate or multiple ADRs per patient are possible; missing fields, no psychiatric/drug misuse history, and abuse/dependence diagnosis not made per international standards; PRR >1 may reflect sampling variation, reporting errors, bias, duplicates, or other causes; privacy limits disclosure.
- The text also makes evident: no total exposure denominator was available to calculate a fatal toxicity index; EV lacked details on pre-discontinuation dosage, withdrawal symptom range/intensity/time-frame, and concurrent psychopathological conditions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 2 Not valid · 35 Not checked · 55 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“According to the 2015 Norwegian Prescription Database, antipsychotic-related, sales' figures, the pattern of quetiapine dispensing in Norway was likely to reflect a predominant off-label use of the molecule, although the paper however made no mention of olanzapine data [65].”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Introduction
What the sources say
- Partly supportedcites [65] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says off-label prescribing of quetiapine has increased markedly in Finland and other countries. It does not report 2015 Norwegian Prescription Database figures or establish that off-label use predominated in Norway; its sales tables concern Finland. (LLM, conf=0.86)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Consistent with previous literature findings [51], the XR formulations were here represented in only a minimal proportion (e.g.6.3%) of cases.”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Discussion
What the sources say
- Could not verifycites [51] sourceExperimental — accuracy not yet measured
The Results report non-medical olanzapine use but do not distinguish XR formulations. The Discussion contains a 6.3% figure, but it refers to poisoning deaths in Ireland in which olanzapine was detected, not the proportion of XR cases. Searches for XR and extended-release formulations found no relevant passage. (LLM, conf=0.77)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The resulting PRR values suggested that the misuse/abuse-; dependence-; and withdrawal-related ADRs were more frequently reported for quetiapine (respectively, 1.07; 1.01; and 5.25) in comparison with olanzapine (see Table 1).”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Quetiapine versus olanzapine; PRR Computation
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The resulting PRR values suggested that the misuse/abuse-; dependence-; and withdrawal-related ADRs were more frequently reported for quetiapine (respectively, 1.07; 1.01; and 5.25) in comparison with olanzapine (see Table 1).”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Quetiapine versus olanzapine; PRR Computation
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The resulting PRR values suggested that the misuse/abuse-; dependence-; and withdrawal-related ADRs were more frequently reported for quetiapine (respectively, 1.07; 1.01; and 5.25) in comparison with olanzapine (see Table 1).”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Quetiapine versus olanzapine; PRR Computation
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
41 more claims
Create a free account to see all 94 claims and to verify the 61 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 20
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even venlafaxine, at mega dosages, can be misused and abused (38; Table 1); this is consistent with desvenlafaxine, being an inhibitor of NA transporter activities, further increasing the rate of DA turnover in the prefrontal cortex (39).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“In the 884-patient quetiapine misuse/abuse/dependence/withdrawal group (18,112 ADRs), 368 (45.2%; 2,979 ADRs) fatalities were identified”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Related Fatalities
Reported 45.2 · recomputed 41.628959
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“opiates/opioids (identified in n=82; 35.9%).”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Olanzapine ADRs
Reported 35.9 · recomputed 34.599156
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Antidepressants (in n=114/288, 48.1% of cases”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Conclusions
Reported 48.1 · recomputed 39.583333
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Other Adverse Events Olanzapine (D) 49,868 49,868/55,100=0.9050Total (C1+C2+C3+C4+C5+C6+C7+C8+D) 55,100”
§ Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database > Conclusions
Reported 55100 · recomputed 54046
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Is sex important? Gender differences in bipolar disorder
Diflorio, A., & Jones, I. (2010) · International Review of Psychiatry · doi:10.3109/09540261.2010.514601 · Cited by 330
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Self-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Kapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 284
Sarker, A., O’Connor, K., Ginn, R., Scotch, M., Smith, K., Malone, D., & Gonzalez, G. (2016) · Drug Safety · doi:10.1007/s40264-015-0379-4 · Cited by 203
Chiappini, S., & Schifano, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0359-y · Cited by 189
Self-citation
Research works printed but not linked: 7
- 2011, Abuse of second-generation antipsychotics: what prescribers need to know, Curr Psychiatry, 10, 77
- 2013, A case series of quetiapine addiction/dependence, Ger J Psychiatr, 16, 152
- 2010, Is seroquel developing an illicit reputation for misuse/abuse?, Psychiatry (Edgmont), 7, 13
- 2015, Abuse liability of quetiapine (Xeroquel®): analysis of the literature, Fundam Clin Pharmacol, 29, 27
- 2007, Letter to the editor. Quetiapine addiction?, Am J Psychiatry, 164, 1
- 2010, Olanzapine dependence, German J Psychiatry, 13, 51
- 2017, [Surveillance system on drug abuse: interest of the French national OPPIDUM program of French addictovigilance network], Therapie, 72, 491
Cited by
New/emerging psychoactive substances and associated psychopathological consequences
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021) · Psychological Medicine · doi:10.1017/s0033291719001727 · Cited by 119
Self-citationIs There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano, F., & Chiappini, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00239 · Cited by 38
Self-citationChiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33
Self-citationTapering opioids: a comprehensive qualitative review
Davis, M. P., Digwood, G., Mehta, Z., & McPherson, M. L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2019.12.10 · Cited by 33
Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Self-citation
Metadata
- Authors
- Chiappini, S., & Schifano, F.
- Affiliations
- University of Hertfordshire (GB)
- Corresponding author
- Chiappini, Stefania
- Schifano, Fabrizio
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2018-02
- Volume
- 38
- Issue
- 1
- Pages
- 72-79
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W2768865188
- Semantic Scholar
- 92f0c2f40205cc6f85bd40a2303ff189e5ff6334
- Cited by
- 44
- References
- 68
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 4
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (acceptedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion, cc-by-nc)
- Funders
- European Commission (JUST/2013/DPIP/AG/4823)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- quetiapine, olanzapine, atypical antipsychotics, drug abuse, drug addiction, withdrawal, adverse drug reactions, EudraVigilance, intranasal administration, intravenous administration, pharmacovigilance
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adolescent, Adult, Benzodiazepines, Child, European Union, Female, Humans, Male, Middle Aged, Substance Withdrawal Syndrome, Antipsychotic Agents, Databases, Factual, Adverse Drug Reaction Reporting Systems, Substance-Related Disorders, Young Adult, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database. https://app.cochat.ai/papers/10.1097/jcp.0000000000000814
- The paper
- Chiappini, S., & Schifano, F. (2018). Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000814
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.